Rexgenero receives Scientific Advice letter from the Medicines & Healthcare products Regulatory Agency (MHRA)

25/11/2015

Rexgenero receives scientific advice from the MHRA (the UK pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero planned phase III study with REX-001 in critical limb ischemia following a meeting with MHRA on 17th September 2015. The MHRA confirmed that the proposed multi-centre, randomized placebo-controlled design as well as the dose is acceptable.

Ixaka Appoints Karen Miller as Chief Scientific Officer

12/07/2022

London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

27/06/2022

REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…

Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

21/03/2022

London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…

innovative cell therapies